Amicus Therapeutics/$FOLD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Amicus Therapeutics

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Ticker

$FOLD
Sector
Primary listing

Employees

499

FOLD Metrics

BasicAdvanced
$2.5B
-
-$0.12
0.51
-

What the Analysts think about FOLD

Analyst ratings (Buy, Hold, Sell) for Amicus Therapeutics stock.

Bulls say / Bears say

Total net product revenues for Q2 2025 were $154.7 million, up 18% at constant exchange rates, marking the 17th consecutive quarter of double-digit CER growth (GlobeNewswire).
Pombiliti + Opfolda net product sales jumped 63% year-over-year to $25.8 million, supported by strong demand and launches in five new countries (GlobeNewswire).
The pivotal Phase 3 study for DMX-200 in focal segmental glomerulosclerosis is expected to finish enrollment by year-end, expanding Amicus’s rare disease pipeline and diversifying future revenue streams (GlobeNewswire).
GAAP operating expenses rose 48% to $148.9 million, while non-GAAP operating expenses increased 56% to $127.8 million, reflecting increased cash burn from higher R&D and licensing costs (GlobeNewswire).
The company posted a GAAP net loss of $24.4 million in Q2 2025, wider than the $15.7 million loss a year earlier, highlighting persistent unprofitability (GlobeNewswire).
Pombiliti + Opfolda full-year 2025 revenue guidance was revised downward to 50–65% CER growth from the previous 65–85%, citing delayed patient starts in new markets and higher-than-expected U.K. VPAG rebates, pointing to execution risks (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2025.

FOLD Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FOLD Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FOLD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs